نتایج جستجو برای: intranasal vaccination

تعداد نتایج: 67825  

2016
Yulia A. Desheva Galina F. Leontieva Tatiana A. Kramskaya Tatiana A. Smolonogina Kornelia B. Grabovskaya Irina V. Kiseleva Larisa G. Rudenko Alexander N. Suvorov

BACKGROUND Secondary bacterial influenza complications are a common cause of excesses morbidity and mortality, which determines the need to develop means for specific prophylaxis. Group B streptococcal infection is especially common cause of pneumonia among children and the elderly with underlying conditions. Here we investigate in a mouse model the effects of combined intranasal immunization u...

2017
David E Place David R Williamson Yevgeniy Yuzefpolskiy Bhuvana Katkere Surojit Sarkar Vandana Kalia Girish S Kirimanjeswara

Progress towards a safe and effective vaccine for the prevention of tularemia has been hindered by a lack of knowledge regarding the correlates of protective adaptive immunity and a lack of tools to generate this knowledge. CD8+ T cells are essential for protective immunity against virulent strains of Francisella tularensis, but to-date, it has not been possible to study these cells in an antig...

Journal: :Infection and immunity 1999
N B Saunders D R Shoemaker B L Brandt E E Moran T Larsen W D Zollinger

Colonization of the human nasopharyngeal region by Neisseria meningitidis is believed to lead to natural immunity. Although the presence of bactericidal antibody in serum has been correlated with immunity to meningococcal disease, mucosal immunity at the portal of entry may also play an important role. This study was undertaken to examine in mice the possibility of safely using native outer mem...

2015
Luzinei da Silva-Couto Raquel Peralva Ribeiro-Romão Andrea Franco Saavedra Beatriz Lilian da Silva Costa Souza Otacílio Cruz Moreira Adriano Gomes-Silva Bartira Rossi-Bergmann Alda Maria Da-Cruz Eduardo Fonseca Pinto

BACKGROUND Previous results have shown that oral and intranasal administration of particulate Leishmania (Leishmania) amazonensis antigens (LaAg) partially protects mice against L. amazonensis infection. However, vaccination studies on species of the subgenus Viannia, the main causative agent of cutaneous and mucosal leishmaniasis in the Americas, have been hampered by the lack of easy-to-handl...

Journal: :Infection and immunity 1999
S Y Seong N H Cho I C Kwon S Y Jeong

Mucosal vaccination of capsular polysaccharide (PS) of Streptococcus pneumoniae and subsequent creation of the first line of immunological defense in mucosa were examined. Mucosal as well as systemic antibody responses to PS were evoked by peroral or intranasal immunization of BALB/c mice with PS-cholera toxin B subunit (CTB) conjugates entrapped in the alginate microspheres (AM). The bacterial...

Journal: :Infection and immunity 1977
D L Ewert C S Eidson D L Dawe

The development of plaque-neutralizing antibody in tracheal washes and hemagglutination inhibition antibody in serum was followed after intratracheal and intranasal or intramuscular inoculation of 1-, 14-, or 28-day-old chicks with a lentogenic strain of Newcastle disease virus (NDV). Serum antibody could be detected between 7 and 10 days after intratracheal and intranasal vaccination in birds ...

Journal: :Vaccine 1999
M Isaka Y Yasuda S Kozuka T Taniguchi K Matano J Maeyama T Komiya K Ohkuma N Goto K Tochikubo

Nasal mucosal immunization is very attractive for vaccination to prevent various bacterial and viral infectious diseases because of induction of systemic and mucosal immune responses. The aim of the present study was to investigate the possibility of changing the immunization procedure of diphtheria toxoid (DT) from intramuscular or subcutaneous injection to intranasal administration. Intranasa...

Journal: :Journal of virology 1998
S Sasaki K Sumino K Hamajima J Fukushima N Ishii S Kawamoto H Mohri C R Kensil K Okuda

Induction of mucosal and cell-mediated immunity is critical for development of an effective vaccine against human immunodeficiency virus (HIV). We compared intramuscular and intranasal immunizations with a DNA vaccine encoding env of HIV-1 and evaluated the QS-21 saponin adjuvant for augmentation of the systemic and mucosal immune responses to HIV-1 in a murine model. Vaccination via the two ro...

Journal: :Clinical and vaccine immunology : CVI 2015
Vyjayanthi Krishnan Bo H Andersen Christine Shoemaker Gloria S Sivko Kevin P Tordoff Gregory V Stark Jianfeng Zhang Tsungwei Feng Matthew Duchars M Scot Roberts

AdVAV is a replication-deficient adenovirus type 5-vectored vaccine expressing the 83-kDa protective antigen (PA83) from Bacillus anthracis that is being developed for the prevention of disease caused by inhalation of aerosolized B. anthracis spores. A noninferiority study comparing the efficacy of AdVAV to the currently licensed Anthrax Vaccine Absorbed (AVA; BioThrax) was performed in New Zea...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید